Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal

Riley J Lizotte,1 John A Kappes,2 Billie J Bartel,2 Katie M Hayes,1 Veronica L Lesselyoung1 1Pharmacy Department, Rapid City Regional Hospital, Rapid City, SD, USA; 2Pharmacy Practice, South Dakota State University, Brookings, SD, USA Background: In severe alcohol withdrawal (AW), benzodiazepines...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lizotte RJ, Kappes JA, Bartel BJ, Hayes KM, Lesselyoung VL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9299401976194957b8018a7adc4e8885
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9299401976194957b8018a7adc4e8885
record_format	dspace
spelling	oai:doaj.org-article:9299401976194957b8018a7adc4e88852021-12-02T07:29:21ZEvaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal1179-1438https://doaj.org/article/9299401976194957b8018a7adc4e88852014-10-01T00:00:00Zhttp://www.dovepress.com/evaluating-the-effects-of-dexmedetomidine-compared-to-propofol-as-adju-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438 Riley J Lizotte,1 John A Kappes,2 Billie J Bartel,2 Katie M Hayes,1 Veronica L Lesselyoung1 1Pharmacy Department, Rapid City Regional Hospital, Rapid City, SD, USA; 2Pharmacy Practice, South Dakota State University, Brookings, SD, USA Background: In severe alcohol withdrawal (AW), benzodiazepines may be inadequate to control symptoms. In many situations, benzodiazepine dosing escalates despite no additional efficacy and introduces potential toxicities. Severe cases of AW may require additional agents to control symptoms. Case reports and studies have shown benefits with dexmedetomidine and propofol in severe AW, but these agents have not been compared with one another. This study compares the effects of dexmedetomidine and propofol on benzodiazepine and haloperidol utilization in patients with AW. Methods: A retrospective chart review was completed on 41 patients with AW who received adjunctive dexmedetomidine or propofol. The primary objective was to compare benzodiazepine and haloperidol utilization before and after initiation of dexmedetomidine or propofol. Secondary measures included AW and sedation scoring, analgesic use, intensive care unit length of stay, rates of intubation, and adverse events. Results: Among the dexmedetomidine and propofol groups, significant reductions in benzodiazepine (P≤0.0001 and P=0.043, respectively) and haloperidol (P≤0.0001 and P=0.026, respectively) requirements were observed. These reductions were comparable between groups (P=0.933 and P=0.465, respectively). A trend toward decreased intensive care unit length of stay in the dexmedetomidine group (123.6 hours vs 156.5 hours; P=0.125) was seen. Rates of intubation (14.7% vs 100%) and time of intubation (19.9 hours vs 97.6 hours; P=0.002) were less in the dexmedetomidine group. Incidence of hypotension was 17.6% in the dexmedetomidine group vs 28.5% in the propofol group. Incidence of bradycardia was 17.6% in the dexmedetomidine group vs 0% in the propofol group. No differences were observed in other secondary outcomes. Conclusion: In patients with severe AW who require sedation, both dexmedetomidine and propofol have unique and advantageous properties. Both agents appear to have equivalent efficacy in reducing AW-related symptoms and benzodiazepine and haloperidol requirements. These results should be validated in a larger, prospective trial. Keywords: dexmedetomidine, propofol, benzodiazepines, alcohol, withdrawalLizotte RJKappes JABartel BJHayes KMLesselyoung VLDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 171-177 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Lizotte RJ Kappes JA Bartel BJ Hayes KM Lesselyoung VL Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
description	Riley J Lizotte,1 John A Kappes,2 Billie J Bartel,2 Katie M Hayes,1 Veronica L Lesselyoung1 1Pharmacy Department, Rapid City Regional Hospital, Rapid City, SD, USA; 2Pharmacy Practice, South Dakota State University, Brookings, SD, USA Background: In severe alcohol withdrawal (AW), benzodiazepines may be inadequate to control symptoms. In many situations, benzodiazepine dosing escalates despite no additional efficacy and introduces potential toxicities. Severe cases of AW may require additional agents to control symptoms. Case reports and studies have shown benefits with dexmedetomidine and propofol in severe AW, but these agents have not been compared with one another. This study compares the effects of dexmedetomidine and propofol on benzodiazepine and haloperidol utilization in patients with AW. Methods: A retrospective chart review was completed on 41 patients with AW who received adjunctive dexmedetomidine or propofol. The primary objective was to compare benzodiazepine and haloperidol utilization before and after initiation of dexmedetomidine or propofol. Secondary measures included AW and sedation scoring, analgesic use, intensive care unit length of stay, rates of intubation, and adverse events. Results: Among the dexmedetomidine and propofol groups, significant reductions in benzodiazepine (P≤0.0001 and P=0.043, respectively) and haloperidol (P≤0.0001 and P=0.026, respectively) requirements were observed. These reductions were comparable between groups (P=0.933 and P=0.465, respectively). A trend toward decreased intensive care unit length of stay in the dexmedetomidine group (123.6 hours vs 156.5 hours; P=0.125) was seen. Rates of intubation (14.7% vs 100%) and time of intubation (19.9 hours vs 97.6 hours; P=0.002) were less in the dexmedetomidine group. Incidence of hypotension was 17.6% in the dexmedetomidine group vs 28.5% in the propofol group. Incidence of bradycardia was 17.6% in the dexmedetomidine group vs 0% in the propofol group. No differences were observed in other secondary outcomes. Conclusion: In patients with severe AW who require sedation, both dexmedetomidine and propofol have unique and advantageous properties. Both agents appear to have equivalent efficacy in reducing AW-related symptoms and benzodiazepine and haloperidol requirements. These results should be validated in a larger, prospective trial. Keywords: dexmedetomidine, propofol, benzodiazepines, alcohol, withdrawal
format	article
author	Lizotte RJ Kappes JA Bartel BJ Hayes KM Lesselyoung VL
author_facet	Lizotte RJ Kappes JA Bartel BJ Hayes KM Lesselyoung VL
author_sort	Lizotte RJ
title	Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
title_short	Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
title_full	Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
title_fullStr	Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
title_full_unstemmed	Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
title_sort	evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/9299401976194957b8018a7adc4e8885
work_keys_str_mv	AT lizotterj evaluatingtheeffectsofdexmedetomidinecomparedtopropofolasadjunctivetherapyinpatientswithalcoholwithdrawal AT kappesja evaluatingtheeffectsofdexmedetomidinecomparedtopropofolasadjunctivetherapyinpatientswithalcoholwithdrawal AT bartelbj evaluatingtheeffectsofdexmedetomidinecomparedtopropofolasadjunctivetherapyinpatientswithalcoholwithdrawal AT hayeskm evaluatingtheeffectsofdexmedetomidinecomparedtopropofolasadjunctivetherapyinpatientswithalcoholwithdrawal AT lesselyoungvl evaluatingtheeffectsofdexmedetomidinecomparedtopropofolasadjunctivetherapyinpatientswithalcoholwithdrawal
_version_	1718399415164600320

Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal

Ejemplares similares